Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.

J Clin Med Res · 2018 · PMC6089574 · PMID 30116437

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significanceP = 0.066so close (0.05 < p ≤ 0.1)

After 24 weeks of treatment with ipragliflozin, HbA1c in the H and M groups was significantly decreased, and these significant reductions persisted until 104 weeks (P < 0.001, respectively), whereas HbA1c in the L group tended to be decreased at 104 weeks but the reduction did not reach statistical significance (P = 0.066) ( Fig. 2a ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.